Point72 Asset Management L.P. Acquires Shares of 63,554 Enovis Co. (NYSE:ENOV)

Point72 Asset Management L.P. acquired a new stake in Enovis Co. (NYSE:ENOV) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 63,554 shares of the company’s stock, valued at approximately $2,789,000.

Several other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Enovis by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 5,486,130 shares of the company’s stock valued at $240,731,000 after purchasing an additional 75,348 shares during the period. DAVENPORT & Co LLC grew its holdings in Enovis by 6.0% in the fourth quarter. DAVENPORT & Co LLC now owns 2,782,341 shares of the company’s stock valued at $121,181,000 after purchasing an additional 157,216 shares during the period. Royce & Associates LP grew its holdings in Enovis by 2.8% in the fourth quarter. Royce & Associates LP now owns 2,470,576 shares of the company’s stock valued at $108,409,000 after purchasing an additional 66,891 shares during the period. River Road Asset Management LLC grew its holdings in Enovis by 3.8% in the fourth quarter. River Road Asset Management LLC now owns 1,238,357 shares of the company’s stock valued at $54,339,000 after purchasing an additional 45,762 shares during the period. Finally, Boston Partners grew its holdings in Enovis by 27.1% in the fourth quarter. Boston Partners now owns 1,048,532 shares of the company’s stock valued at $46,034,000 after purchasing an additional 223,816 shares during the period. 98.45% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ENOV. Canaccord Genuity Group lowered their price target on Enovis from $75.00 to $70.00 and set a “buy” rating on the stock in a research note on Wednesday, May 14th. JMP Securities lowered their price target on Enovis from $62.00 to $55.00 and set a “market outperform” rating on the stock in a research note on Friday, May 9th. Finally, Needham & Company LLC lowered their price target on Enovis from $64.00 to $57.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $58.00.

Enovis Stock Performance

Shares of NYSE:ENOV opened at $34.45 on Wednesday. Enovis Co. has a 1 year low of $29.32 and a 1 year high of $51.31. The firm has a market capitalization of $1.97 billion, a PE ratio of -15.73 and a beta of 1.79. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The business’s 50 day moving average price is $35.10 and its 200-day moving average price is $41.32.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.07. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The firm had revenue of $558.83 million for the quarter, compared to the consensus estimate of $558.80 million. During the same quarter last year, the business posted $0.50 earnings per share. The firm’s revenue was up 8.2% compared to the same quarter last year. As a group, equities research analysts expect that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.